Literature DB >> 29090684

Neuroactive Steroids and Affective Symptoms in Women Across the Weight Spectrum.

Laura E Dichtel1, Elizabeth A Lawson1, Melanie Schorr1, Erinne Meenaghan2, Margaret Lederfine Paskal2, Kamryn T Eddy3, Graziano Pinna4, Marianela Nelson4, Ann M Rasmusson5,6, Anne Klibanski1, Karen K Miller1.   

Abstract

3α-5α-Tetrahydroprogesterone, a progesterone metabolite also known as allopregnanolone, and 5α-androstane-3α,17β-diol, a testosterone metabolite also known as 3α-androstanediol, are neuroactive steroids and positive GABAA receptor allosteric modulators. Both anorexia nervosa (AN) and obesity are complicated by affective comorbidities and hypothalamic-pituitary-gonadal dysregulation. However, it is not known whether neuroactive steroid levels are abnormal at the extremes of the weight spectrum. We hypothesized that serum allopregnanolone and 3α-androstanediol levels would be decreased in AN compared with healthy controls (HC) and negatively associated with affective symptoms throughout the weight spectrum, independent of body mass index (BMI). Thirty-six women were 1 : 1 age-matched across three groups: AN, HC, and overweight/obese (OW/OB). AN were amenorrheic; HC and OW/OB were studied in the follicular phase. Fasting serum neuroactive steroids were measured by gas chromatography/mass spectrometry. Mean Hamilton depression and anxiety scores were highest in AN (p<0.0001). Mean serum allopregnanolone was lower in AN and OW/OB than HC (AN 95.3±56.4 vs OW/OB 73.8±31.3 vs HC 199.5±167.8 pg/ml, p=0.01), despite comparable mean serum progesterone. Allopregnanolone levels, but not progesterone levels, were negatively associated with depression and anxiety symptom severity, independent of BMI. Serum 3α-androstanediol levels did not differ among groups and were not associated with depression or anxiety scores, despite a significant negative association between free testosterone levels and both anxiety and depression severity. In conclusion, women at both extremes of the weight spectrum have low mean serum allopregnanolone, which is associated with increased depression and anxiety severity, independent of BMI. Neuroactive steroids such as allopregnanolone may be potential therapeutic targets for depression and anxiety in traditionally treatment-resistant groups, including AN.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29090684      PMCID: PMC5916351          DOI: 10.1038/npp.2017.269

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  51 in total

1.  Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

Authors:  Christina Wang; Glenn Cunningham; Adrian Dobs; Ali Iranmanesh; Alvin M Matsumoto; Peter J Snyder; Thomas Weber; Nancy Berman; Laura Hull; Ronald S Swerdloff
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

Review 2.  Comorbidity and outcome in eating disorders.

Authors:  D B Herzog; K M Nussbaum; A K Marmor
Journal:  Psychiatr Clin North Am       Date:  1996-12

3.  Neuropsychopharmacological properties of neuroactive steroids in depression and anxiety disorders.

Authors:  Daniela Eser; Cornelius Schüle; Elena Romeo; Thomas C Baghai; Flavia di Michele; Augusto Pasini; Peter Zwanzger; Frank Padberg; Rainer Rupprecht
Journal:  Psychopharmacology (Berl)       Date:  2005-10-25       Impact factor: 4.530

4.  Plasma levels of neuroactive steroids are increased in untreated women with anorexia nervosa or bulimia nervosa.

Authors:  P Monteleone; M Luisi; B Colurcio; E Casarosa; P Monteleone; R Ioime; A R Genazzani; M Maj
Journal:  Psychosom Med       Date:  2001 Jan-Feb       Impact factor: 4.312

Review 5.  Neuropsychopharmacological properties of neuroactive steroids.

Authors:  R Rupprecht; F Holsboer
Journal:  Steroids       Date:  1999 Jan-Feb       Impact factor: 2.668

6.  gamma-Aminobutyric acid, acting through gamma -aminobutyric acid type A receptors, inhibits the biosynthesis of neurosteroids in the frog hypothalamus.

Authors:  J L Do-Rego; G A Mensah-Nyagan; D Beaujean; D Vaudry; W Sieghart; V Luu-The; G Pelletier; H Vaudry
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

7.  Hypercortisolemia is associated with severity of bone loss and depression in hypothalamic amenorrhea and anorexia nervosa.

Authors:  Elizabeth A Lawson; Daniel Donoho; Karen K Miller; Madhusmita Misra; Erinne Meenaghan; Janet Lydecker; Tamara Wexler; David B Herzog; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

8.  Effects of antidepressant treatment on neuroactive steroids in major depression.

Authors:  E Romeo; A Ströhle; G Spalletta; F di Michele; B Hermann; F Holsboer; A Pasini; R Rupprecht
Journal:  Am J Psychiatry       Date:  1998-07       Impact factor: 18.112

9.  Decreased corticolimbic allopregnanolone expression during social isolation enhances contextual fear: A model relevant for posttraumatic stress disorder.

Authors:  Fabio Pibiri; Marianela Nelson; Alessandro Guidotti; Erminio Costa; Graziano Pinna
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

10.  Depression-like behavior of aged male and female mice is ameliorated with administration of testosterone or its metabolites.

Authors:  Cheryl A Frye; Alicia A Walf
Journal:  Physiol Behav       Date:  2009-02-28
View more
  9 in total

1.  Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women: A Pilot Study.

Authors:  Laura E Dichtel; Maren Nyer; David Mischoulon; Maurizio Fava; Karen K Miller; Christina Dording; Lauren B Fisher; Cristina Cusin; Benjamin G Shapero; Paola Pedrelli; Allison S Kimball; Elizabeth M Rao
Journal:  J Clin Psychiatry       Date:  2020-06-09       Impact factor: 4.384

2.  Effect of ganaxolone in patients with posttraumatic stress disorder.

Authors:  Tomoyuki Kawada
Journal:  Psychopharmacology (Berl)       Date:  2018-04-04       Impact factor: 4.530

3.  A Randomized Placebo-Controlled Trial of Low-Dose Testosterone Therapy in Women With Anorexia Nervosa.

Authors:  Allison Kimball; Melanie Schorr; Erinne Meenaghan; Katherine N Bachmann; Kamryn T Eddy; Madhusmita Misra; Elizabeth A Lawson; Elana Kreiger-Benson; David B Herzog; Stuart Koman; Robert J Keane; Seda Ebrahimi; David Schoenfeld; Anne Klibanski; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

Review 4.  Gut feelings: the microbiota-gut-brain axis on steroids.

Authors:  Sik Yu So; Tor C Savidge
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-11-03       Impact factor: 4.052

5.  The allopregnanolone to progesterone ratio across the menstrual cycle and in menopause.

Authors:  Allison Kimball; Laura E Dichtel; Maren B Nyer; David Mischoulon; Lauren B Fisher; Cristina Cusin; Christina M Dording; Nhi-Ha Trinh; Albert Yeung; Melanie S Haines; Joshua C Sung; Graziano Pinna; Ann M Rasmusson; Linda L Carpenter; Maurizio Fava; Anne Klibanski; Karen Klahr Miller
Journal:  Psychoneuroendocrinology       Date:  2019-11-14       Impact factor: 4.905

Review 6.  Overview of the Molecular Steps in Steroidogenesis of the GABAergic Neurosteroids Allopregnanolone and Pregnanolone.

Authors:  Jennifer J Liang; Ann M Rasmusson
Journal:  Chronic Stress (Thousand Oaks)       Date:  2018-12-19

7.  Biomarkers for PTSD at the Interface of the Endocannabinoid and Neurosteroid Axis.

Authors:  Graziano Pinna
Journal:  Front Neurosci       Date:  2018-08-06       Impact factor: 4.677

8.  Prenatal Exposure to Bisphenols and Phthalates and Postpartum Depression: The Role of Neurosteroid Hormone Disruption.

Authors:  Melanie H Jacobson; Cheryl R Stein; Mengling Liu; Marra G Ackerman; Jennifer K Blakemore; Sara E Long; Graziano Pinna; Raquel Romay-Tallon; Kurunthachalam Kannan; Hongkai Zhu; Leonardo Trasande
Journal:  J Clin Endocrinol Metab       Date:  2021-06-16       Impact factor: 5.958

Review 9.  Allopregnanolone: An overview on its synthesis and effects.

Authors:  Silvia Diviccaro; Lucia Cioffi; Eva Falvo; Silvia Giatti; Roberto Cosimo Melcangi
Journal:  J Neuroendocrinol       Date:  2021-06-29       Impact factor: 3.870

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.